Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии, психотерапии и психосоматической патологии ФПКМР Российского университета дружбы народов, Москва
Список исп. литературыСкрыть список 1. Абрамова Л.И., Олейчик И.В., Иванец Н.Н. и др. Ципралекс (эсциталопрам) при лечении тяжелых эндогенных депрессий: особенности терапевтической эффективности и переносимости. Психиатр. и психофармакотер. 2007; 2. 2. Громов Л.А., Чайка Л.А., Гомон О.Н., Меркулова Ю.В. Селективные ингибиторы обратного захвата серотонина: современное положение в терапии депрессий. Рацион. фармакотерапия в кардиологии. 2008; 3. 3. Изнак А.Ф., Поздеева Е.А., Изнак Е.В. «Чистые» стереоизомеры – новое направление повышения эффективности антидепрессантов (обзор литературы). Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2008; 1. 4. Медведев В.Э. Сигма-рецепторы: роль в лечении аффективных расстройств. Неврология, нейропсихиатрия и психосоматика. 2012; 2: 105–7. 5. Медведев В.Э. Возможность комбинированной терапии депрессий мелатонинергическим и трициклическими антидепрессантами. Психиатр. и психофармакотер. 2012; 1: 53–6. 6. Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессий у пациентов с ишемической болезнью сердца. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2010; 3: 31–6. 7. Auquier P, Robtail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiat Clin Pract 2003; 7: 259–68. 8. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Intern Clin Psychopharmacol 2006; 21: 159–69. 9. Baumann P, Zullino DF, Eap ChB. Enantiomer’s potential in psychopharmacology – a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433–44. 10. Bielski RJ, Bose A, Chang ChCh. Clinical psychiatry a double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiat 2005; 17: 65–9. 11. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriat Psychiat 2008; 16: 14–20. 12. Boulenger J-P, Huusom AK, Florea I et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Opin 2006; 22. 13. Burke WJ, Kratochvil ChJ. Stereoisomers in psychiatry: the case of escitalopram. Primary Care Companion. J Clin Psychiat 2002; 4: 20–4. 14. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Психиатр. и психофармакотер. 2009; 2. 15. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Poster presented at the 3rd International Forum on Mood and Anxiety Disorders. Monte Carlo, Monaco, 2002. 16. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconom 2003; 21 (16): 1185–209. 17. Davidson Jr, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiat 2005; 66 (11): 1441–6. 18. Demyttenaere K, Hemels ME, Hudry J, Annemans L. Cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Therapeut 2005; 1: 111–24. 19. Dhillon S, Scott LJ, Ploster GL. Эсциталопрам. Обзор по применению препарата при лечении тревожных расстройств. Ч. 1. Психиатр. и психофармакотер. 2007; 3. 20. Francois C, Toumi M, Aakhus MA, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Eur J Health Econom 2003; 4: 12–9. 21. Hansen R, Gaynes B, Thieda P et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiat Serv 2008; 59: 1121–30. 22. Hemels ME, Kasper S, Walter E, Einarson ThR. Cost-effectiveness of escitalopram vs citalopram in the treatment of severe depression. Ann Pharmacother 2004; 38: 954–60. 23. Kasper S, Baldwin DS, Lönn SL, Boulenger J-P. Superiority of escitalopram to paroxetine in the treatment of depression. Europ Neuropsychopharmacol 2009; 19: 229–37. 24. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiat Neurosci 2006; 31 (2): 122–31. 25. Leonard B, Taylor D. Escitalopram – translating molecular properties into clinical benefit: reviewing the evidence in major depression. J Psychopharmacol 2010; 24 (8): 1143–52. 26. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149–55. 27. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59 (3): 268–75. 28. Möller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiat 2007; 40: 53–7. 29. Montgomery SA, Lader M, Burger V et al. Escitalopram and paroxetine in fixed doses for the treatment of social anxiety disorder (SAD). Nord J Psychiat 2003; 57: 103. 30. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiol 2004; 50: 57–64. 31. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychomarmacol 2005; 20: 131–7. 32. Ong A, Lan G. Escitalopram in Philippine clinical practice: result of an open-label, observational study in 2920 outpatients with depression. Philippine J Inter Med 2011; 49: 100–4. 33. Rapaport MH, Bose A, Zeng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiat 2004; 65: 44–9. 34. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiet 2005; 21: 26–32. 35. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiat 2003; 64 (11): 1322–7. 36. Stamouli SS, Yfantis A, Lamboussis E et al. Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Exp Opin Pharmacother 2009; 10: 937–45. 37. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiat 2005; 17 (2): 71–5. 38. Stein DJ, Kasper S, Andersen EW et al. Escitalopram in the treatment of social anxiety disorder. Depres and Anxiet 2004; 20: 175–81. 39. Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J 2010; 51: 61–73. 40. von Moltke LL, Greenblatt DJ, Giancarlo GM et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102–9. 41. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram vs citalopram in the treatment of severe depression in the UK. Clin Ther 2005; 27: 486–96. 42. Wade AG, Fernandez JL, Francois C et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconom 2008; 26: 969–81. 43. Wang PS, Patrick AR, Dormuth CR et al. The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiat Serv 2008; 59 (4): 377–83. 44. Wingen M, Bothmer J, Langer S, Ramaekers J. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine and placebo: a crossover trial. J Clin Psychiat 2005; 66: 436–43. 45. World Health Organization. Depression. http://www.who.int/mental_health/ management/depression/definition/definition/en